Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27410812 | 0.98 | CES1 (0.44) | CES1CES2DGKAALDH1A1TP53 | |
| Hydrazine SCHEMBL27464055 | 0.96 | CES1 (0.42) | CES1CES2DGKAALDH1A1TP53 | |
| SCHEMBL522691 | 0.93 | DGKA (0.54) | CES1CES2DGKAALDH1A1LMNA | |
| SCHEMBL2394516 | 0.92 | ALDH1A1 (0.48) | CES1CES2DGKAALDH1A1TP53 | |
| SCHEMBL62214 | 0.91 | DGKA (0.57) | CES1CES2DGKAALDH1A1LMNA | |
| SCHEMBL9985650 | 0.91 | DGKA (0.57) | CES1CES2DGKAALDH1A1LMNA | |
| SCHEMBL3121472 | 0.91 | DGKA (0.57) | CES1CES2DGKAALDH1A1LMNA | |
| SCHEMBL3662225 | 0.91 | DGKA (0.57) | CES1CES2DGKAALDH1A1LMNA | |
| SCHEMBL3823631 | 0.91 | DGKA (0.57) | CES1CES2DGKAALDH1A1LMNA | |
| SCHEMBL5732818 | 0.91 | DGKA (0.57) | CES1CES2DGKAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 664 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119735735-A | Polymer solid electrolyte of fluorine-free interface layer, in-situ polymerization preparation method and application | 深圳大学 | 2025-04-01 | — | — | CN | claimed |
| US-20240018088-A1 | SEPARATION AND PURIFICATION METHOD OF 2-NITROETHANOL | FUDAN UNIVERSITY (CN) | 2024-01-18 | — | — | US | claimed |
| CN-116410093-A | Separation and purification method of 2-nitroethanol | 复旦大学 | 2023-07-11 | — | — | CN | claimed |
| CN-110642936-B | Method for preparing teriparatide | 深圳翰宇药业股份有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-113636975-A | Boscalid hapten, preparation method thereof, antigen, antibody and application thereof | 深圳市易瑞生物技术股份有限公司 | 2021-11-12 | — | — | CN | claimed |
| CN-113480474-A | Sulfoxaflor hapten, preparation method thereof, antigen, antibody and application thereof | 深圳市易瑞生物技术股份有限公司 | 2021-10-08 | — | — | CN | claimed |
| EP-3088955-B1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2020-06-03 | — | — | EP | claimed |
| CN-106094450-B | Resist composition and patterning method | 信越化学工业株式会社 | 2020-05-05 | — | — | CN | claimed |
| US-9927708-B2 | Pattern forming process and shrink agent | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-03-27 | — | — | US | claimed |
| US-9921479-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | claimed |
| EP-1549622-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | Elian Pharmaceuticals Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004033436-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC (US) | 2004-04-22 | — | — | WO | claimed |
| CN-1476123-A | Gel electrolyte secondary cell and mfg. method thereof | 夏普株式会社 | 2004-02-18 | — | — | CN | claimed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | claimed |
| CN-1438727-A | Polymer electrolyte and lithium cell using same | SAMSUNG SDI CO LTD (KR) | 2003-08-27 | — | — | CN | claimed |
| CN-1283183-A | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | DARWIN DISCOVERY LTD (GB) | 2001-02-07 | — | — | CN | claimed |
| CN-1094730-A | Peptides | SANDOZ LTD (CH) | 1994-11-09 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018088-A1 | SEPARATION AND PURIFICATION METHOD OF 2-NITROETHANOL | NUCB2, DNPH1, ECE2 | CES1 420/4885CES2 44/4885DGKA 633/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | CES1 1677/4885CES2 2985/4885DGKA 1379/4885 |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | BDKRB1, BDKRB2, HRH2 | CES1 1443/4885CES2 2439/4885DGKA 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.